Neumora Therapeutics is trading at $0.74 (+6.30%) during the September 22, 2026 session; no clear company-specific announcement or fresh catalyst was identified.
- Recent NMRA-215 toxicology news supports planned clinical advancement but dates from July and does not directly explain the September 22 increase.
- Broader markets are modestly positive, but available evidence does not establish a direct macro cause.